🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very exciting study! Will "priming" by HDAC inhibitors improve efficacy and response to lutetium Lu 177 (pluvicto) and PSMA ADCs? 🤔🤔🤔

ADCs are so 🔥🔥 right now. Check our systematic review in touchONCOLOGY on the evolving landscape of enfortumab vedotin in bladder cancer. touchoncology.com/bladder-cancer… Petros Grivas Dimitrios (Dimitri) Makrakis Ali Khaki Fred Hutch Cancer Center UW Urology Hsieh Lab Dan L Duncan Comprehensive Cancer Center BCM Department of Urology Rebecca Johnson

Fantastic to write this systematic review on enfortumab vedotin with Rafee Talukder Ali Khaki Dimitrios (Dimitri) Makrakis we tried to cover comprehensively the data so far. Interested in FDA Oncology review of EV103 data & future EV302 trial! Uromigos Jonathan Rosenberg MD Tom Powles Vadim Koshkin MD

Promising results with neoadjuvant ipi+nivo in pts with cisplatin-ineligible MIBC. Needs validation with phase II/III studies. Definitely area of unmet need. Guru P. Sonpavde, MD Petros Grivas Ali Khaki @practiceupdate

Excellent editorial by super mentee Rafee Talukder in relevant topic! Guru P. Sonpavde, MD @practiceupdate Ali Khaki Dimitra R. Bakaloudi MD, MS, MPA Shilpa Gupta Jessica Hawley MD MS Fred Hutch Cancer Center Dr. Bishoy M. Faltas Minas Economides, MD Dimitrios (Dimitri) Makrakis Leonidas N. Diamantopoulos, MD Andrew Portuguese Roger Li Ashish M. Kamat, MD, MBBS Philippe spiess Andrea Necchi

Houston #Rockets fans after a three-year, 236-game rebuild

Thank you, really enjoyed it!! Best TBT ever!!

OncLive.com OncLive SOSS Andrea Apolo, M.D. Shilpa Gupta Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition BladderCancerCanada IBCG IBCN OncoAlert MashupMD Dimitra R. Bakaloudi MD, MS, MPA Rafee Talukder Ali Khaki Vivek Subbiah, MD Vadim Koshkin MD Pedro C Barata, MD MSc FACP Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Uromigos Ashish M. Kamat, MD, MBBS @BhatiaS_MD

Happy to share that EV-103 Cohort K is out in JCO: Enfortumab Vedotin +/- Pembrolizumab in Cisplatin-Ineligible Patients With LA/mUC ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology Memorial Sloan Kettering Cancer Center Christopher Hoimes Daniel Petrylak Thomas Flaig Bladder Cancer Advocacy Network Rana McKay, MD, FASCO

Congratulations indeed! We are looking forward to seeing everyone at #BCANTT23.

Outcomes with immune checkpoint inhibitors in patients with MTAP alterations in advanced #UrothelialCarcinoma. Rafee Talukder Fred Hutch Cancer Center joins Petros Grivas University of Washington to discuss the effects of MTAP loss on survival rates on UroToday > bit.ly/3XYRl3v

And here you are the full class of the 2023 #BCANTT23 John Quale Travel fellows

Fantastic talk by Ali Khaki #AIBCCR on histology subtypes in #bladdercancer sparking discussion with Hikmat Al Ahmadie Matt Milowsky citing our 2 neoadjuvant trials Fred Hutch Cancer Center Rafee Talukder ICONIC trial Andrea Apolo, M.D. we need trials, tumor heterogeneity is a challenge IBCG

Incredibly honored to receive one of the Conquer Cancer, the ASCO Foundation ASCO merit awards and be part of this amazing group of brilliant minds ⭐️ Thankful to my mentors Petros Grivas Jonathan L Wright and team Ali Khaki Rafee Talukder University of Washington Fred Hutch Cancer Center

⭐️My good friend Petros Grivas and I talk about the importance of Mentorship in Oncology. We discuss people we admire such as Dr. Neeraj Agarwal and Dr. Monty Pal for being outstanding mentors. Also we discuss Dimitra R. Bakaloudi MD, MS, MPA journey to win the Conquer Cancer, the ASCO Foundation merit award.

I am delighted to share our manuscript evaluating Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in pts with #Urothelialcancer treated with ICIs Thanks to our amazing team Petros Grivas Ali Khaki Rafee Talukder University of Washington Fred Hutch Cancer Center sciencedirect.com/science/articl… (1/7)

⭐️Dr. Scott Tykodi Fred Hutch Cancer Center gives a masterful discussion on the only adjuvant study that was positive for RCC. He also gives an intriguing discussion of the use of NIVO/IPI for 1st line metastatic RCC with favorable risk . Petros Grivas Rafee Talukder OncoDaily

⭐️Loved this informative talk by Dr. Hiba Khan Fred Hutch Cancer Center . Updated table on the PARP inhibitor combination trials . Also a very thoughtful discussion for treatment escalation candidates for non-metastatic prostate cancer. Petros Grivas Evan Hall Martin Ma